HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Gilead Sciences (GILD)
Gilead Sciences: Strong Market Position and Positive Long-Term Outlook Justify Buy Rating
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $135
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating
Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating
Gilead Sciences Analyst Ratings
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $125 to $140
Jefferies Keeps Their Buy Rating on Gilead Sciences (GILD)
Morgan Stanley Raises Price Target on Gilead Sciences to $135 From $130, Keeps Overweight Rating
Gilead Sciences: Hold Rating Amid Mixed Performance and Future Opportunities
Gilead Sciences: Strong Growth Prospects and Strategic Positioning Support Buy Rating
Gilead Sciences (GILD) Gets a Buy From Oppenheimer
Research Alert: Mixed Q1 Performance, 2025 Product Sales And Adjusted Eps Guidance Maintained
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $110 to $125
Optimistic Adjustments and Operational Efficiency Drive Buy Rating for Gilead Sciences
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Gets a Hold From Truist Financial